newsfilter
← Earnings
Earnings Releases·

Senseonics Holdings, Inc. — Third Quarter 2026 Earnings Summary

  • Revenue surged 140% year-over-year to $19.6 million in Q3 2026, driven by a 160% U.S. revenue increase to $16.8 million, while gross margin expanded to 62% from 43% in the prior year period.
  • Full-year 2026 guidance was raised to $68 million–$70 million in global net revenue (93%–98% YoY growth) and gross margins exceeding 60%, reflecting strong Eversense 365 momentum.
  • Strategic initiatives include a Q4 2026 commercial launch of the Eversense 365 and iLet® Bionic Pancreas integration with Beta Bionics, alongside the initiation of the "Freedom" next-generation CGM study.
  • Net loss widened to $32.7 million ($0.50 per share) from $19.5 million in Q3 2025 due to increased R&D and SG&A expenses, though the company maintains $126.6 million in cash and equivalents.
  • Commercial operations for Eversense 365 are now fully in-house globally, with U.S. active prescribers up 90% YoY and the EON Care network expanding to over 100 inserters.
Company
SENSEONICS HOLDINGS INC
Sector
Healthcare
Industry
Medical Devices